lanoteplase

Lanoteplase is a recombinant, second-generation tissue plasminogen activator (tPA) developed as a thrombolytic agent for the treatment of acute myocardial infarction and other thrombotic disorders. It is a serine protease engineered from tPA by deletion and point mutation, resulting in increased half-life compared to alteplase. Lanoteplase binds to fibrin within blood clots and cleaves the Arg-Val bond in plasminogen, generating active plasmin that degrades fibrin clots, thereby restoring blood flow in occluded vessels. Clinical trials demonstrated its efficacy as a single bolus intravenous injection with dose-dependent reperfusion rates comparable or superior to alteplase; however, development was discontinued due to safety concerns including higher rates of intracranial hemorrhage at certain doses[1][2][3].

Brand names

Oneplas

Other names

lanoteplase (genetical recombination)lanoteplase [INN]Lanoteplase [WHO-DD]